data exclusivity

Data exclusivity refers to a form of regulatory protection that prevents competitors from relying on the originator’s preclinical and clinical test data when seeking marketing authorization for pharmaceutical or certain other regulated products.

Data exclusivity is distinct from patent protection. While patents protect inventions, data exclusivity protects the substantial investment required to generate safety, efficacy, and quality data submitted to regulatory authorities. During the exclusivity period, generic or competing applicants are generally prohibited from relying on the originator’s regulatory dossier to obtain approval.

The duration and scope of data exclusivity vary among jurisdictions. In the European Union, pharmaceutical products are generally subject to the “8+2+1” regulatory protection framework, while other countries may apply different periods and conditions.

In Türkiye, data exclusivity is recognized for certain pharmaceutical products in accordance with Turkish pharmaceutical legislation and international obligations. Data exclusivity may continue to provide protection even when patent protection is unavailable, invalid, or has expired.

Data exclusivity plays an important role in pharmaceutical innovation by encouraging investment in research, clinical development, and regulatory approval processes while balancing the eventual entry of generic medicines into the market.